Wegovy for menopause weight loss: what we know, what's uncertain, and who to ask

You've put the weight on during perimenopause and nothing seems to shift it

This is a question our prescribers hear most weeks: "I eat the same as I always have, I exercise, but since my periods became irregular the weight just settled around my middle and won't move." That description is familiar for good reason. Oestrogen helps regulate fat distribution, and as levels fall through perimenopause and menopause, the body tends to lay down more visceral fat, the kind that sits around the abdomen and carries its own metabolic risks. The usual tools (calorie restriction, more activity) still help, but they work against a shifted hormonal baseline.

Wegovy works by mimicking GLP-1, a gut hormone involved in appetite regulation and the rate at which food leaves the stomach. It doesn't replace oestrogen or address the hormonal cause of menopausal weight gain, but it does reduce appetite and energy intake in a way that many women find easier to sustain than willpower alone. In the STEP 1 trial, published in the New England Journal of Medicine, semaglutide 2.4mg produced an average weight reduction of around 15% over 68 weeks in adults with obesity or overweight and a weight-related condition. That trial wasn't menopause-specific, but a meaningful proportion of participants were women in the relevant age range. If you want to understand whether Wegovy works for menopause weight gain, our dedicated page explores what the evidence does and doesn't show for this specific group.

If you want a deeper look at the perimenopause angle specifically, the page on Wegovy for perimenopause weight gain covers that period in more detail.

What's known, and where the uncertainty honestly sits

What we can say with confidence: Wegovy holds a UK licence for weight management in adults with a BMI of 30 or above, or 27 or above alongside a qualifying condition such as high blood pressure, high cholesterol, or type 2 diabetes. NICE's appraisal of semaglutide for weight loss (NICE TA875) supports its use within specialist services. The mechanism (slowing gastric emptying, reducing appetite signals) doesn't depend on whether weight gain was hormonally driven or not.

Where the uncertainty sits: there are no large randomised trials isolating menopausal women as a specific group, so claims that Wegovy is "designed for" menopause weight loss would be inaccurate. What exists is biological plausibility and clinical experience, many prescribers see good responses in this group, but individual results vary, and menopause status alone doesn't predict how well semaglutide will work for a given person.

For women already on HRT, the picture is broadly reassuring but requires a conversation. NHS England's guidance on weight-management injections advises considering transdermal HRT (patches or gels rather than tablets) while on tirzepatide due to effects on oral drug absorption; semaglutide's profile is somewhat different, but the principle of checking your current medications with a prescriber before starting applies equally here. The NHS England page on weight-management injections covers this in plain language.

Post-menopausal women often have other conditions in the picture (cardiovascular risk, prediabetes, osteoarthritis) that may themselves be relevant to eligibility, and our page on whether diabetics can take Wegovy for weight loss is a useful read if type 2 diabetes or prediabetes is part of your picture. Worth raising all of them at your consultation rather than just the weight.

Safety considerations specific to this stage of life

The side-effect profile of Wegovy is dominated by gastrointestinal effects: nausea, loose stools, constipation and reflux are the most reported, particularly in the first weeks or after a dose increase. These tend to settle. They're worth knowing about not because they're dangerous in most people, but because they can sometimes mask or mimic symptoms that are also common in perimenopause, bloating, nausea, changes in bowel habit. Keeping your GP informed matters.

Pancreatitis is a less common but more serious risk. In January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis as a known effect of GLP-1 medicines that warrants attention: if you develop severe, persistent stomach pain that radiates to the back, seek urgent medical help rather than waiting for it to pass. Side effects and suspected adverse reactions can be reported directly at the MHRA's Yellow Card scheme.

On pregnancy: Wegovy is not recommended for anyone who is pregnant, breastfeeding, or actively trying to conceive. For most women well into menopause this isn't a live question, but for those in perimenopause (where pregnancy is still possible even with irregular cycles) reliable contraception remains important. If that applies to you, raise it explicitly with your prescriber. Our separate page on Wegovy and pregnancy covers the full guidance if you need it.

Suitability is always individual. A prescriber needs to look at your BMI, your current medications, your medical history and your goals before making a clinical decision. No page, however thorough, replaces that review.

Your next step: a clinical conversation, not a search for reassurance

If you've read this far, you're probably looking for a straight answer about whether Wegovy is right for you specifically. That answer genuinely can't be given here, not because of caution for its own sake, but because the right call depends on your individual circumstances. What can happen quickly is a proper clinical assessment.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not an automated system) and reviewed on the same day you submit it. If treatment is clinically appropriate, it's dispatched the same day (for orders placed before midday, Monday to Friday) and arrives free the next working day in plain packaging via DPD. You can read more about how Wegovy works or look at the full range of treatment options before starting, or go straight to the consultation if you're ready. You can also verify our pharmacy registration at the GPhC register (registration number 9012878) at pharmacyregulation.org, it takes thirty seconds and it's the most useful check you can do when choosing an online pharmacy. When you're ready, speak to our prescribers and get a clinical view on your situation.